Redsense offsets loan raised in connection with directed share issue
The Board of Directors of Redsense Medical AB (publ.) has resolved, in accordance with the authorization given by the Annual General Meeting on 6 May 2019, to increase the Company’s share capital with SEK 30,514.90 through a directed new share issue.
The new share issue is directed to Gerhard Dal and Modelio Equity AB. The share price is set to SEK 10.38 under the agreement, which corresponds to a 10 percent discount compared to the volume-weightedaverage priceduring the period between 2019-10-09 and 2019-10-29. The amount of the loan offset by the issue is MSEK 3 plus interest.
As the directed issue is carried out, the number of shares in the Company increases from 11,869,765 to 12,174,914. The dilutive effect is approximately 2.5 percent for existing shareholders.
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysistreatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage tominimizeblood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on 31 October 2019.